ストックスクリーナーアプリを入手
5.475
4.78%
-0.275
プレマーケット:
5.35
-0.125
-2.28%
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register
Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trend Tracker for (ALDX) - news.stocktradersdaily.com
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average – Here’s Why - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX - Business Wire
BTIG maintains Aldeyra stock Buy rating, $11 target By Investing.com - Investing.com Canada
Aldeyra Therapeutics Beats Investor Suit Over Eye Drug Misses - Bloomberg Law News
(ALDX) On The My Stocks Page - Stock Traders Daily
Biotech Wins Dismissal Of Investor Fraud Claims - Law360
ALDX stock touches 52-week high at $6.93 amid robust gains - Investing.com Australia
ALDX stock touches 52-week high at $6.93 amid robust gains By Investing.com - Investing.com South Africa
Tech Stocks Defying Market Volatility: Meet the Pioneers of Tomorrow’s Economy - DSA
High Growth Tech Stocks To Watch In The US March 2025 - Simply Wall St
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Aldeyra Therapeutics CEO Scheduled for Fireside Chat at Major Healthcare Conference - Stock Titan
Aldeyra Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Q1 Earnings Estimate for ALDX Issued By HC Wainwright - Defense World
How to Take Advantage of moves in (ALDX) - Stock Traders Daily
Aldeyra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., expected to drive market - Barchart
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin - openPR
Aldeyra Therapeutics (NASDAQ:ALDX) Receives Buy Rating from HC Wainwright - Defense World
Aldeyra Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics Inc [ALDX] Insider Activity: An Update for Investors - Knox Daily
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Best Stocks Under $10 • Charts Updated Daily - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Aldeyra Therapeutics, Inc. (ALDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
(ALDX) Trading Report - Stock Traders Daily
AlphaCentric Advisors LLC Acquires New Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
In-Depth Analysis Of The Chronic Plaque Psoriasis Market: Key Drivers, Trends, Growth Opportunities And - EIN News
Global Microtome Market to Exhibit Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA - openPR
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation ... - The Bakersfield Californian
ALDX stock touches 52-week high at $6.6 amid robust annual gains - MSN
Why Aldeyra Therapeutics Inc (NASDAQ: ALDX) Is A Great Stock Pick For Momentum Investors - Stocks Register
Dry Eye Disease Clinical Trial Pipeline | 45+ Companies Pioneering the Future of Treatment - EIN News
(ALDX) Proactive Strategies - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stake Raised by SG Americas Securities LLC - Defense World
Dry Eye Disease Market Poised for Major Advancements by 2034, Reveals DelveInsight - WICZ
Aldeyra Therapeutics Inc (ALDX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
Exclusive Fireside Chat: Aldeyra CEO Reveals Company Strategy at Major Healthcare Conference - StockTitan
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Growth in Short Interest - MarketBeat
How the (ALDX) price action is used to our Advantage - Stock Traders Daily
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):